Last reviewed · How we verify
ERYPO®, Janssen-Cilag
ERYPO® (epoetin alfa) stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells to increase red blood cell production.
ERYPO® (epoetin alfa) stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells to increase red blood cell production. Used for Anemia associated with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy, Anemia in patients undergoing elective surgery.
At a glance
| Generic name | ERYPO®, Janssen-Cilag |
|---|---|
| Also known as | EPREX®, Solution for i.v. injection |
| Sponsor | Sandoz |
| Drug class | Erythropoiesis-stimulating agent (ESA) |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
Epoetin alfa is a recombinant human erythropoietin that mimics the natural hormone responsible for regulating red blood cell production. It binds to erythropoietin receptors on erythroid progenitor cells in the bone marrow, promoting their proliferation, differentiation, and maturation into mature red blood cells. This mechanism is used to treat anemia by increasing hemoglobin and hematocrit levels.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia in patients with cancer receiving chemotherapy
- Anemia in patients undergoing elective surgery
Common side effects
- Hypertension
- Headache
- Thrombotic events (venous thromboembolism, stroke)
- Injection site reactions
- Flu-like symptoms
- Pure red cell aplasia (rare)
Key clinical trials
- Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients (PHASE3)
- Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients (PHASE3)
- Erythropoietin and Platelet Activation Markers (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ERYPO®, Janssen-Cilag CI brief — competitive landscape report
- ERYPO®, Janssen-Cilag updates RSS · CI watch RSS
- Sandoz portfolio CI